“Expanded 2026 ADA Guidance on SGLT2i in CKD Starting at EGFR ≥20 and Combining With a Nonsteroidal MRA”. 2026. Diabzen 4 (17): 34-35. https://thediabzen.com/index.php/d/article/view/60.